Research & Literature

Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit.

Gera N, Yang A, Holtzman TS, et al.

PloS one 2015; (10(5)):e0125269 doi:10.1371/journal.pone.0125269.

Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations.

Lok E, Swanson KD, Wong ET

Expert review of medical devices 2015; (12(6)):717-26 doi:10.1586/17434440.2015.1086641.

Role of Physical Therapy Intervention in Patients With Life-Threatening Illnesses.

Putt K, Faville KA, Lewis D, et al.

The American journal of hospice & palliative care 2017; (34(2)):186-196 doi:10.1177/1049909115623246.

Molecular classification of gliomas.

Masui K, Mischel PS, Reifenberger G

Handbook of clinical neurology 2016; (134()):97-120.

Corticosteroids compromise survival in glioblastoma.

Pitter KL, Tamagno I, Alikhanyan K, et al.

Brain : a journal of neurology 2016; (139(Pt 5)):1458-71 doi:10.1093/brain/aww046.

Current and future strategies for treatment of glioma.

Bush NA, Chang SM, Berger MS

Neurosurgical review 2017; (40(1)):1-14 doi:10.1007/s10143-016-0709-8.

Levetiracetam for seizure prevention in brain tumor patients: a systematic review.

Nasr ZG, Paravattil B, Wilby KJ

Journal of neuro-oncology 2016; (129(1)):1-13 doi:10.1007/s11060-016-2146-5.

Rapid malignant transformation of low-grade astrocytoma in a pregnant woman.

Hanada T, Rahayu TU, Yamahata H, et al.

The journal of obstetrics and gynaecology research 2016; (42(10)):1385-1389 doi:10.1111/jog.13072.

Surgical resection of incidental diffuse gliomas involving eloquent brain areas. Rationale, functional, epileptological and oncological outcomes.

Lima GLO, Dezamis E, Corns R, et al.

Neuro-Chirurgie 2017; (63(3)):250-258 doi:10.1016/j.neuchi.2016.08.007.

Network Plasticity and Intraoperative Mapping for Personalized Multimodal Management of Diffuse Low-Grade Gliomas.

Ghinda CD, Duffau H

Frontiers in surgery 2017; (4()):3 doi:10.3389/fsurg.2017.00003.

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, et al.

The New England journal of medicine 2017; (376(11)):1027-1037 doi:10.1056/NEJMoa1611977.

Milestones of the last 10 years: CNS cancer.

Marosi C, Preusser M

Memo 2017; (10(1)):18-21 doi:10.1007/s12254-016-0309-x.

Is fluorescence-guided surgery with 5-ala in eloquent areas for malignant gliomas a reasonable and useful technique?

Picart T, Armoiry X, Berthiller J, et al.

Neuro-Chirurgie 2017; (63(3)):189-196 doi:10.1016/j.neuchi.2016.12.005.

Characterization of gliomas: from morphology to molecules.

Ferris SP, Hofmann JW, Solomon DA, Perry A

Virchows Archiv : an international journal of pathology 2017; (471(2)):257-269 doi:10.1007/s00428-017-2181-4.

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.

Mun EJ, Babiker HM, Weinberg U, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2018; (24(2)):266-275 doi:10.1158/1078-0432.CCR-17-1117.

A systematic review of perioperative seizure prophylaxis during brain tumor resection: the case for a multicenter randomized clinical trial.

Chandra V, Rock AK, Opalak C, et al.

Neurosurgical focus 2017; (43(5)):E18 doi:10.3171/2017.8.FOCUS17442.

Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.

Cardona AF, Rojas L, Wills B, et al.

Journal of neuro-oncology 2018; (136(2)):363-371 doi:10.1007/s11060-017-2660-0.

High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.

Feyissa AM, Worrell GA, Tatum WO, et al.

Neurology 2018; (90(13)):e1119-e1125 doi:10.1212/WNL.0000000000005216.

Improved survival of Swedish glioblastoma patients treated according to Stupp.

Bruhn H, Strandéus M, Milos P, et al.

Acta neurologica Scandinavica 2018; (138(4)):332-337 doi:10.1111/ane.12966.

Physical Rehabilitation and Occupational Therapy.

Capozzi LC, Dolgoy ND, McNeely ML

Oral and maxillofacial surgery clinics of North America 2018; (30(4)):471-486 doi:10.1016/j.coms.2018.06.008.

Optimizing Outpatient Total Ankle Replacement from Clinic to Pain Management.

Taylor MA, Parekh SG

The Orthopedic clinics of North America 2018; (49(4)):541-551 doi:10.1016/j.ocl.2018.06.003.

Video-Teleconferencing in Pediatric Neuro-Oncology: Ten Years of Experience.

Amayiri N, Swaidan M, Abuirmeileh N, et al.

Journal of global oncology 2018; (4()):1-7 doi:10.1200/JGO.2016.008276.

The Evolving Role of the Oncologic Neurosurgeon: Looking Beyond Extent of Resection in the Modern Era.

Bowden SG, Han SJ

Frontiers in oncology 2018; (8()):406 doi:10.3389/fonc.2018.00406.

IDH mutant astrocytoma: biomarkers for prognostic stratification and the next frontiers.

Brandner S, Jaunmuktane Z

Neuropathology and applied neurobiology 2019; (45(2)):91-94 doi:10.1111/nan.12521.

Approved Treatments for Patients with Recurrent High-grade Gliomas.

Laub CK, Stefanik J, Doherty L

Seminars in oncology nursing 2018; (34(5)):486-493 doi:10.1016/j.soncn.2018.10.005.

Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma.

Serventi J, Behr J

Seminars in oncology nursing 2018; (34(5)):443-453 doi:10.1016/j.soncn.2018.10.009.

Nursing Guide to Management of Major Symptoms in Patients with Malignant Glioma.

Siegel C, Armstrong TS

Seminars in oncology nursing 2018; (34(5)):513-527 doi:10.1016/j.soncn.2018.10.014.

Value-based Practice: Integration of Cancer Rehabilitation and Palliative Care in Oncology Services.

Zhu Y

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 2018; (33(4)):204-209 doi:10.24920/003523.

Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies.

Dubinski D, Hattingen E, Senft C, et al.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2019; (39(8)):1460-1468 doi:10.1177/0271678X19859847.

Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.

Verburg N, Koopman T, Yaqub MM, et al.

Neuro-oncology 2020; (22(3)):412-422 doi:10.1093/neuonc/noz180.

Efficacy of perioperative anticonvulsant prophylaxis in seizure-naïve glioma patients: A meta-analysis.

Wang X, Zheng X, Hu S, et al.

Clinical neurology and neurosurgery 2019; (186()):105529 doi:10.1016/j.clineuro.2019.105529.

Evaluation of VEGF, FGF and PDGF and Serum Levels of Inflammatory Cytokines in Patients with Glioma and Meningioma in Southern Iran.

Shamsdin SA, Mehrafshan A, Rakei SM, Mehrabani D

Asian Pacific journal of cancer prevention : APJCP 2019; (20(10)):2883-2890 doi:10.31557/APJCP.2019.20.10.2883.

Tumour-associated macrophage-derived interleukin-1 mediates glioblastoma-associated cerebral oedema.

Herting CJ, Chen Z, Maximov V, et al.

Brain : a journal of neurology 2019; (142(12)):3834-3851 doi:10.1093/brain/awz331.

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.

Kim YZ, Kim CY, Lim J, et al.

Brain tumor research and treatment 2019; (7(2)):63-73 doi:10.14791/btrt.2019.7.e42.

Readability of Online Neuro-Oncology-Related Patient Education Materials from Tertiary-Care Academic Centers.

Ammanuel SG, Edwards CS, Alhadi R, Hervey-Jumper SL

World neurosurgery 2020; (134()):e1108-e1114 doi:10.1016/j.wneu.2019.11.109.

Cancer care and occupational therapy: A scoping review.

Wallis A, Meredith P, Stanley M

Australian occupational therapy journal 2020; (67(2)):172-194 doi:10.1111/1440-1630.12633.

Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.

Ferreira MSV, Sørensen MD, Pusch S, et al.

Journal of neuro-oncology 2020; (147(1)):1-14 doi:10.1007/s11060-020-03394-y.

Correlation between IDH, ATRX, and TERT promoter mutations in glioma.

Ohba S, Kuwahara K, Yamada S, et al.

Brain tumor pathology 2020; (37(2)):33-40 doi:10.1007/s10014-020-00360-4.

A Glioma Presenting as a Posterior Circulation Stroke.

Lu F, Fowler A, Tam K, Camara-Lemarroy CR

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2020; (47(5)):691-692 doi:10.1017/cjn.2020.77.

Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.

Cahill DP

Neurosurgery clinics of North America 2021; (32(1)):23-29 doi:10.1016/j.nec.2020.09.006.

Characteristics of Fluorescent Intraoperative Dyes Helpful in Gross Total Resection of High-Grade Gliomas-A Systematic Review.

Mazurek M, Kulesza B, Stoma F, et al.

Diagnostics (Basel, Switzerland) 2020; (10(12)) doi:10.3390/diagnostics10121100.

Canine Gliomatosis Cerebri: Morphologic and Immunohistochemical Characterization Is Supportive of Glial Histogenesis.

Rissi DR, Donovan TA, Porter BF, et al.

Veterinary pathology 2021; (58(2)):293-304 doi:10.1177/0300985820980704.

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.

Birzu C, French P, Caccese M, et al.

Cancers 2020; (13(1)) doi:10.3390/cancers13010047.

Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole.

Kast RE, Burns TC, Halatsch ME

Neuro-Chirurgie 2021; (67(5)):508-515 doi:10.1016/j.neuchi.2020.12.008.

Physical Therapy, Occupational Therapy, and Speech Language Pathology in the Emergency Department: Specialty Consult Services to Enhance the Care of Older Adults.

Pontius EA, Anderson RS

Emergency medicine clinics of North America 2021; (39(2)):419-427 doi:10.1016/j.emc.2021.01.005.

Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey.

Schäfer N, Bumes E, Eberle F, et al.

Journal of neuro-oncology 2021; (153(3)):479-485 doi:10.1007/s11060-021-03784-w.

Impact of Immunohistochemical profiling of Glioblastoma multiforme on clinical outcomes: Real-world scenario in resource limited setting.

Kumar N, Elangovan A, Madan R, et al.

Clinical neurology and neurosurgery 2021; (207()):106726 doi:10.1016/j.clineuro.2021.106726.

Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH.

de Biase D, Acquaviva G, Visani M, et al.

The Journal of molecular diagnostics : JMD 2021; (23(9)):1185-1194 doi:10.1016/j.jmoldx.2021.06.004.

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.

Kurdi M, Shafique Butt N, Baeesa S, et al.

Pathology oncology research : POR 2021; (27()):1609778 doi:10.3389/pore.2021.1609778.

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.

Perez A, Huse JT

Current neurology and neuroscience reports 2021; (21(12)):67 doi:10.1007/s11910-021-01153-8.

Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.

Nishikawa T, Watanabe R, Kitano Y, et al.

Brain tumor pathology 2022; (39(1)):14-24 doi:10.1007/s10014-021-00418-x.

Glioblastoma vaccine tumor therapy research progress.

Zhao T, Li C, Ge H, et al.

Chinese neurosurgical journal 2022; (8(1)):2 doi:10.1186/s41016-021-00269-7.

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma.

Huang LE

Biomedicines 2022; (10(2)) doi:10.3390/biomedicines10020246.

Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.

Whitfield BT, Huse JT

Brain pathology (Zurich, Switzerland) 2022; (32(4)):e13062 doi:10.1111/bpa.13062.

Prognostic value of O 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas.

Lam K, Eldred BSC, Kevan B, et al.

Neuro-oncology advances 2022; (4(1)):vdac030 doi:10.1093/noajnl/vdac030.

HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.

Felix M, Friedel D, Jayavelu AK, et al.

Neuro-oncology 2022; (24(12)):2121-2132 doi:10.1093/neuonc/noac111.

Effect of High-Quality Nursing Based on Comprehensive Nursing on the Postoperative Quality of Life and Satisfaction of Patients with Malignant Glioma.

Gong X, Wu W, Xing D, et al.

Evidence-based complementary and alternative medicine : eCAM 2022; (2022()):9345099 doi:10.1155/2022/9345099.

Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.

Kurokawa R, Kurokawa M, Baba A, et al.

Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(5)):1474-1493 doi:10.1148/rg.210236.

Clinical Profile, Pathology, and Molecular Typing of Gliomas with Oligodendroglial Morphology: A Single Institutional Experience.

Lavanya G, Uppin MS, Alugolu R, et al.

Neurology India 2022; (70(3)):1020-1024 doi:10.4103/0028-3886.349641.

Blood-Brain Barrier Alterations and Edema Formation in Different Brain Mass Lesions.

Solar P, Hendrych M, Barak M, et al.

Frontiers in cellular neuroscience 2022; (16()):922181 doi:10.3389/fncel.2022.922181.

The need for comprehensive multidisciplinary programs, complex interventions, and precision medicine for bicuspid aortic valve disease.

Crawford EE, McCarthy PM, Malaisrie SC, et al.

Annals of cardiothoracic surgery 2022; (11(4)):369-379 doi:10.21037/acs-2021-bav-207.

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.

Fortin Ensign SP, Jenkins RB, Giannini C, et al.

Neuro-oncology 2023; (25(1)):28-36 doi:10.1093/neuonc/noac205.

The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review.

Swildens KX, Sillevis Smitt PAE, van den Bent MJ, et al.

Neuro-oncology advances 2022; (4(1)):vdac087 doi:10.1093/noajnl/vdac087.

National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.

Ostrom QT, Shoaf ML, Cioffi G, et al.

Neuro-oncology 2023; (25(4)):799-807 doi:10.1093/neuonc/noac198.

Association of Cognitive Impairment With Rate of Functional Gain Among Older Adults With Stroke.

Cogan AM, Weaver JA, Davidson LF, et al.

Journal of the American Medical Directors Association 2022; (23(12)):1963.e1-1963.e6 doi:10.1016/j.jamda.2022.07.026.

Current and promising treatment strategies in glioma.

Śledzińska P, Bebyn M, Furtak J, et al.

Reviews in the neurosciences 2023; (34(5)):483-516 doi:10.1515/revneuro-2022-0060.

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.

Ostrom QT, Price M, Neff C, et al.

Neuro-oncology 2022; (24(Suppl 5)):v1-v95 doi:10.1093/neuonc/noac202.

5-Aminolevulinic Acid Imaging of Malignant Glioma.

Li G, Rodrigues A, Kim L, et al.

Surgical oncology clinics of North America 2022; (31(4)):581-593 doi:10.1016/j.soc.2022.06.002.

Prevalence of seizures in brain tumor: A meta-analysis.

Audrey C, Lim KS, Ahmad Zaki R, et al.

Epilepsy research 2022; (187()):107033 doi:10.1016/j.eplepsyres.2022.107033.

Advances in immunotherapy for glioblastoma multiforme.

Mahmoud AB, Ajina R, Aref S, et al.

Frontiers in immunology 2022; (13()):944452 doi:10.3389/fimmu.2022.944452.

Advances in Complex Congenital Tracheoesophageal Anomalies.

Mohammed S, Hamilton TE

Clinics in perinatology 2022; (49(4)):927-941 doi:10.1016/j.clp.2022.07.003.

Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.

Hervey-Jumper SL, Zhang Y, Phillips JJ, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(11)):2029-2042 doi:10.1200/JCO.21.02929.

Review of the Recent Changes in the WHO Classification for Pediatric Brain and Spinal Cord Tumors.

Halfpenny AM, Wood MD

Pediatric neurosurgery 2023; (58(5)):337-355 doi:10.1159/000528957.

Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States.

Neff C, Cioffi G, Waite K, et al.

Neuro-oncology practice 2023; (10(1)):24-33 doi:10.1093/nop/npac079.

Classification and Diagnosis of Adult Glioma: A Scoping Review.

Byun YH, Park CK

Brain & NeuroRehabilitation 2022; (15(3)):e23 doi:10.12786/bn.2022.15.e23.

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al.

The New England journal of medicine 2023; (389(7)):589-601 doi:10.1056/NEJMoa2304194.

A new era for glioma therapy - targeting mutant IDH.

Reardon DA, Cahill DP

Nature reviews. Clinical oncology 2023; (20(11)):737-738 doi:10.1038/s41571-023-00804-8.

Rectovaginal Fistula From Untreated Ulcerative Colitis in Pregnancy: A Case Report and Review of the Literature.

Altshuler PC, Bradford E, van Swaay A, et al.

Cureus 2023; (15(6)):e40662 doi:10.7759/cureus.40662.

A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.

Tran S, Thomas A, Aliouat I, et al.

Neuropathology and applied neurobiology 2023; (49(4)):e12928 doi:10.1111/nan.12928.

Brain tumour genetic network signatures of survival.

Ruffle JK, Mohinta S, Pombo G, et al.

Brain : a journal of neurology 2023; (146(11)):4736-4754 doi:10.1093/brain/awad199.

Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.

Hou Z, Hu J, Liu X, et al.

Journal of neuro-oncology 2023; (164(2)):461-471 doi:10.1007/s11060-023-04420-5.

Peritumoral Edema in Gliomas: A Review of Mechanisms and Management.

Ohmura K, Tomita H, Hara A

Biomedicines 2023; (11(10)) doi:10.3390/biomedicines11102731.

Context-dependent regulation of Notch signaling in glial development and tumorigenesis.

Guo R, Han D, Song X, et al.

Science advances 2023; (9(45)):eadi2167 doi:10.1126/sciadv.adi2167.

Clinical impact of molecular profiling in rare brain tumors.

Pratt D, Penas-Prado M, Gilbert MR

Current opinion in neurology 2023; (36(6)):579-586 doi:10.1097/WCO.0000000000001211.

miRNAs and related genetic biomarkers according to the WHO glioma classification: From diagnosis to future therapeutic targets.

Nikolova E, Laleva L, Milev M, et al.

Non-coding RNA research 2024; (9(1)):141-152 doi:10.1016/j.ncrna.2023.10.003.

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma.

Weller M, Felsberg J, Hentschel B, et al.

Acta neuropathologica 2024; (147(1)):11 doi:10.1007/s00401-023-02662-1.

Review of advanced practice nurse role in infection throughout the hematopoietic stem cell transplant journey.

Gilsenan M, Van Der Linde S, Hill G, Lambros B

Transplant infectious disease : an official journal of the Transplantation Society 2024; (26(2)):e14268 doi:10.1111/tid.14268.

Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States.

Pergolotti M, Wood KC, Kendig TD, Mayo S

Cancers 2024; (16(10)) doi:10.3390/cancers16101927.

Awake Craniotomy for a Frontal Astrocytoma: A Case Report.

Velchev V, Burev S, Ferdinandov D, et al.

Cureus 2024; (16(5)):e59667 doi:10.7759/cureus.59667.

Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria.

Lee Y, Park CK, Park SH

Cancers 2024; (16(11)) doi:10.3390/cancers16112032.

Workforce Challenges for the Neurosurgical Care of Brain Tumors in Low- and Middle-Income Countries: A Scoping Review.

Shakir M, Khowaja AH, Shariq SF, et al.

World neurosurgery 2024; (189()):387-398.e3 doi:10.1016/j.wneu.2024.06.098.

Deep learning-based end-to-end scan-type classification, pre-processing, and segmentation of clinical neuro-oncology studies.

Chakrabarty S, Abidi SA, Mousa M, et al.

Proceedings of SPIE--the International Society for Optical Engineering 2023; (12469()) doi:10.1117/12.2647656.

Central nervous system pediatric multi-disciplinary tumor board: a single center experience.

Russo R, Verdolotti T, Perna A, et al.

BMC cancer 2024; (24(1)):1146 doi:10.1186/s12885-024-12882-7.

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.

Wetzel EA, Nohman AI, Hsieh AL, et al.

Journal of neuro-oncology 2025; (171(2)):373-381 doi:10.1007/s11060-024-04852-7.

Implications of molecular classifications in glioma surgery.

Kalluri AL, Lee JH, Lucas CG, et al.

Journal of neuro-oncology 2025; (171(3)):559-569 doi:10.1007/s11060-024-04883-0.

Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.

Rafanan J, Ghani N, Kazemeini S, et al.

International journal of molecular sciences 2025; (26(3)) doi:10.3390/ijms26030917.

5-Aminolevulinic acid (5-ALA) in paediatric brain tumour surgery-a systematic review and exploration of fluorophore alternatives.

Collins VG, Kanodia C, Yahya QB, et al.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2025; (41(1)):150 doi:10.1007/s00381-025-06810-8.

Epilepsy in patients with pediatric brain tumors: Etiology, treatment & management.

Ku A, Esfahanizadeh A

Seminars in pediatric neurology 2025; (53()):101187 doi:10.1016/j.spen.2025.101187.

Spinal Metastasis from Supratentorial Glioblastoma: A Registry-Based Case Series and a Review of the Literature.

Lau ACK, Wong DK, Cheung JCH, et al.

Cancers 2025; (17(18)) doi:10.3390/cancers17182979.

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

Cloughesy TF, van den Bent MJ, Touat M, et al.

The Lancet. Oncology 2025; (26(12)):1665-1675 doi:10.1016/S1470-2045(25)00472-3.

Clinical Outcome of Patients with Epithelioid Glioblastoma Harboring BRAFV600E Mutation; A Single Institution Experience.

Subramanian P, Das A, Chilukuri S, et al.

South Asian journal of cancer 2025; (14(4)):672-677 doi:10.1055/s-0044-1789605.

From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.

Ortega MA, Fraile-Martinez O, Boaru DL, et al.

Cellular and molecular neurobiology 2026; (46(1)):33 doi:10.1007/s10571-025-01642-1.